Patents by Inventor John Gregory Slatter

John Gregory Slatter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
    Publication number: 20210322408
    Abstract: In an embodiment, therapeutic methods and uses of Bruton's Tyrosine Kinase (BTK) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Inventors: Brian Lannutti, Todd Covey, Allard Kaptein, Dave Johnson, Jay Stamatis, Cecile M. Krejsa, John Gregory Slatter
  • Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
    Publication number: 20190314369
    Abstract: In an embodiment, therapeutic methods and uses of Bruton's Tyrosine Kinase (BTK) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described.
    Type: Application
    Filed: March 15, 2019
    Publication date: October 17, 2019
    Inventors: Brian Lannutti, Todd Covey, Allard Kaptein, Dave Johnson, Jay Stamatis, Cecile M. Krejsa, John Gregory Slatter
  • Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
    Publication number: 20170143712
    Abstract: In an embodiment, therapeutic methods and uses of Bruton's Tyrosine Kinase (BTK) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for a BTK inhibitor for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on BTK occupancies and/or BTK resynthesis rates for B cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described.
    Type: Application
    Filed: February 7, 2017
    Publication date: May 25, 2017
    Inventors: Brian Lannutti, Todd Covey, Allard Kaptein, Dave Johnson, Jay Stamatis, Cecile M. Krejsa, John Gregory Slatter
  • 3,3-diphenylpropylamines useful in therapy
    Patent number: 7291648
    Abstract: Novel 3,3-diphenylpropylamines of the formula and stereoisomers and physiologically acceptable acid addition salt thereof; wherein R1, R2, R3, R4, R5, and R6 are as defined herein; methods of use thereof; and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: November 6, 2007
    Assignee: Pfizer Inc.
    Inventors: John Gregory Slatter, Raymond Charles Grabiak, Robert John Kaufman
  • 3,3-diphenylpropylamines useful in therapy
    Patent number: 7119121
    Abstract: Novel 3,3-diphenylpropylamines of the formula and stereoisomers and physiologically acceptable acid addition salt thereof; wherein R1, R2, R3, R4, R5, and R6 are as defined herein; methods of use thereof; and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: October 10, 2006
    Assignee: Pfizer Inc.
    Inventors: John Gregory Slatter, Raymond Charles Grabiak, Robert John Kaufman
  • Quaternary ammonium compounds
    Patent number: 6946486
    Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: September 20, 2005
    Assignee: Pharmacia & Upjohn Co.
    Inventor: John Gregory Slatter
  • Quaternary ammonium compounds
    Publication number: 20040138253
    Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
    Type: Application
    Filed: October 17, 2003
    Publication date: July 15, 2004
    Inventor: John Gregory Slatter
  • Quaternary ammonium compounds
    Publication number: 20040116519
    Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
    Type: Application
    Filed: October 17, 2003
    Publication date: June 17, 2004
    Inventor: John Gregory Slatter